America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What is AOH1996, and how does it specifically target cancer cells in the body?
**Editor:** Welcome, Dr. Ahmadineja, and thank you for joining us today. We’re excited to discuss the recent breakthroughs from City of Hope Hospital regarding the new cancer treatment.
**Dr. Ahmadineja:** Thank you for having me. It’s a pleasure to be here.
**Editor:** Let’s dive right in. Your team has developed a drug known as AOH1996. Can you briefly explain how it works and its significance in cancer treatment?
**Dr. Ahmadineja:** Certainly! AOH1996 is designed as a targeted chemotherapy drug that specifically targets cancer cells by disrupting their DNA replication process. Think of PCNA—the protein we focus on—as a central hub, like an airport terminal. In cancer cells, this hub is uniquely mutated, allowing us to more effectively zero in on and attack only the diseased cells while sparing the healthy ones.
**Editor:** That sounds promising. What types of cancer have shown positive responses to this drug based on your clinical research?
**Dr. Ahmadineja:** Our studies have demonstrated AOH1996’s effectiveness across various cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. This broad applicability is one of the reasons we’re excited about its potential.
**Editor:** Impressive! You’ve conducted tests on over 70 cancer cell lines. What were some of the key findings from these tests?
**Dr. Ahmadineja:** The results were striking. AOH1996 selectively killed cancer cells by disrupting their normal reproductive cycle, leading to their elimination while leaving healthy cells largely intact. This selectivity is crucial, as it could reduce the harsh side effects often associated with traditional chemotherapy.
**Editor:** That’s a game changer for cancer patients. What are the next steps for this drug following your findings?
**Dr. Ahmadineja:** The next step is very important—advancing to human clinical trials. We are currently in the process of preparing for these trials, which will allow us to assess the drug’s safety and efficacy in actual patients.
**Editor:** Thank you, Dr. Ahmadineja, for sharing these insights. It’s encouraging to see such advancements in the fight against cancer, and we wish you the best of luck with the upcoming trials.
**Dr. Ahmadineja:** Thank you for the opportunity to discuss our work. We’re hopeful for the future of cancer treatment!
